
  
    
      
        Background_NNP
        Cellulose_NNP acetate_NN phthalate_NN (_( CAP_NNP )_) is_VBZ a_DT promising_JJ
        microbicide_NN candidate_NN for_IN prevention_NN of_IN infection_NN by_IN
        sexually_RB transmitted_VBD disease_NN (_( STD_NNP )_) pathogens_NNS ,_, including_VBG
        HIV-_NNP 1_CD [_NN 1_CD 2_CD 3_CD 4_CD 5_CD 6_CD 7_CD ]_NN ._. CAP_NNP inactivates_NNS HIV-_NNP 1_CD and_CC blocks_VBZ
        the_DT coreceptor_NN binding_JJ site_NN on_IN the_DT virus_NN envelope_NN
        glycoprotein_NN gp_NN 120_CD ,_, while_IN leaving_VBG the_DT site_NN for_IN the_DT primary_JJ
        cellular_JJ receptor_NN CD_NNP 4_CD accessible_JJ [_NN 8_CD 9_CD ]_NN Soluble_NNP CD_NNP 4_CD (_( sCD_NN 4_LS )_)
        was_VBD shown_VBN to_TO inhibit_VB HIV-_NNP 1_CD infection_NN by_IN two_CD mechanisms_NNS :_:
        reversible_JJ blockage_NN of_IN virus_NN binding_JJ to_TO receptors_NNS ,_, and_CC
        irreversible_JJ inactivation_NN of_IN virus_NN infectivity_NN [_NN 10_CD ]_NN ._.
        Since_IN CAP_NNP and_CC sCD_NN 4_CD bind_NN to_TO distinct_JJ domains_NNS on_IN the_DT HIV-_NNP 1_CD
        envelope_NN ,_, it_PRP was_VBD of_IN interest_NN to_TO determine_VB whether_IN or_CC not_RB
        these_DT two_CD ligands_NNS affect_VBP virus_NN infectivity_NN synergistically_RB
        as_IN do_VBP other_JJ combinations_NNS of_IN anti-_NN HIV-_NNP 1_CD drugs_NNS and_CC sCD_NN 4_CD [_NN 11_CD
        12_CD ]_NN Binding_NNP of_IN sCD_NN 4_CD leads_VBZ to_TO conformational_NN changes_NNS in_IN
        gp_NN 120_CD [_NN 13_CD 14_CD 15_CD 16_CD 17_CD ]_NN ._. Binding_NNP of_IN gp_NN 120_CD to_TO coreceptors_NNS
        CXCR_NNP 4_CD and_CC CCR_NNP 5_CD ,_, respectively_RB ,_, triggers_VBZ additional_JJ
        conformational_NN changes_NNS in_IN HIV-_NNP 1_CD envelope_NN glycoproteins_NNS [_NN 18_CD
        19_CD ]_NN For_IN these_DT reasons_NNS it_PRP was_VBD of_IN interest_NN to_TO determine_VB
        whether_IN a_DT )_) pretreatment_NN of_IN HIV-_NNP 1_CD with_IN sCD_NN 4_CD would_MD affect_VB
        subsequent_JJ binding_JJ of_IN CAP_NNP to_TO virus_NN particles_NNS ,_, and_CC b_SYM )_) CAP_NNP
        binding_JJ to_TO virus_NN particles_NNS in_IN the_DT presence_NN or_CC absence_NN of_IN
        sCD_NN 4_CD would_MD elicit_NN conformational_NN changes_NNS which_WDT could_MD affect_VB
        HIV-_NNP 1_CD infectivity_NN ._. Such_JJ studies_NNS were_VBD expected_VBN to_TO elucidate_NN
        further_VB the_DT mechanisms_NNS involved_VBN in_IN the_DT antiviral_JJ /_NN virucidal_NN
        activity_NN of_IN CAP_NNP and_CC to_TO contribute_VB to_TO the_DT potential_JJ
        development_NN of_IN microbicides_NNS combining_VBG two_CD or_CC more_JJR
        anti-_NN HIV-_NNP 1_CD compounds_NNS with_IN distinct_JJ target_NN sites_NNS ._.
      
      
        Methods_NNP
        
          Reagents_NNP
          The_DT following_VBG monoclonal_NN antibodies_NNS (_( mAbs_NNS )_) were_VBD used_VBN :_:
          NC-_NNP 1_CD ,_, a_DT mouse_NN mAb_NN raised_VBD against_IN the_DT gp_NN 41_CD six-helix_JJ
          bundle_NN from_IN HIV-_NNP 1_CD IIIB_NNP [_NN 20_CD ]_NN ;_: and_CC anti-p_JJ 24_CD mAb_NN
          (_( ImmunoDiagnostics_NNP ,_, Inc_NNP ._. ,_, Woburn_NNP ,_, MA_NNP )_) ._. Rabbit_NNP antibodies_NNS
          against_IN the_DT gp_NN 41_CD six-helix_JJ bundle_NN were_VBD prepared_VBN as_IN
          described_VBN [_NN 21_CD ]_NN ._. Rabbit_NNP antiserum_NN against_IN HIV-_NNP 1_CD IIIB_NNP
          gp_NN 120_CD was_VBD prepared_VBN as_IN described_VBN [_NN 22_CD ]_NN and_CC shown_VBN to_TO
          cross-react_JJ with_IN HIV-_NNP 1_CD BaL_NNP (_( own_JJ unpublished_JJ data_NNS )_) ._.
          Recombinant_NNP soluble_JJ CD_NNP 4_CD (_( sCD_NN 4_LS )_) was_VBD from_IN Genentech_NNP Inc_NNP ._. ,_,
          South_NNP San_NNP Francisco_NNP ,_, CA_NNP ._. Recombinant_NNP HIV-_NNP 1_CD IIIB_NNP gp_NN 120_CD ,_,
          biotinylated_JJ gp_NN 120_CD and_CC biotinylated_JJ sCD_NN 4_CD were_VBD from_IN
          ImmunoDiagnostics_NNP ,_, Inc_NNP ._. ,_, Woburn_NNP ,_, MA_NNP ._. Purified_NNP recombinant_JJ
          protein_NN A_DT /_NN G_NNP was_VBD from_IN Pierce_NNP ,_, Rockford_NNP ,_, IL_NNP ._. Pelletted_NNP ,_,
          1000_CD -_: fold_VB concentrates_VBZ of_IN HIV-_NNP 1_CD IIIB_NNP (_( 6_CD ._. 8_CD ×_NN 10_CD 10_CD virus_NN
          particles_NNS /_NN ml_NN )_) and_CC BaL_NNP (_( 2_CD ._. 47_CD ×_NN 10_CD 10_CD virus_NN particles_NNS /_NN ml_NN )_) [_NN
          23_CD ]_NN were_VBD from_IN Advanced_NNP Biotechnologies_NNP ,_, Inc_NNP ._. ,_, Columbia_NNP ,_,
          MD_NNP ._. Biotin_NNP labeled_VBD goat_NN anti-mouse_JJ IgG_NNP and_CC anti-rabbit_JJ
          IgG_NNP were_VBD from_IN Roche_NNP Diagnostics_NNPS Corporation_NNP ,_,
          Indianapolis_NNP ,_, IN_IN ._. Chicken_NN serum_NN was_VBD from_IN OEM_NNP Concepts_NNP ,_,
          Toms_NNP River_NNP ,_, NJ_NNP ._. Antiserum_NNP to_TO phthalate_NN was_VBD prepared_VBN by_IN
          immunization_NN of_IN rabbits_NNS with_IN phthalic_JJ anhydride_NN treated_VBD
          rabbit_NN serum_NN albumin_NN [_NN 24_CD ]_NN ._. Horseradish_NNP peroxidase_NN
          (_( HRP_NNP )_) labeled_VBN streptavidin_NN was_VBD from_IN Zymed_NNP ,_, South_NNP San_NNP
          Francisco_NNP ,_, CA_NNP ._. HRP_NNP was_VBD quantitated_JJ using_VBG a_DT kit_NN from_IN
          Kirkegaard_NNP &_CC Perry_NNP Laboratories_NNPS ,_, Inc_NNP ._. ,_, Gaithersburg_NNP ,_,
          MD_NNP ._. Enzyme_NNP linked_VBD immunosorbent_NN assay_NN (_( ELISA_NNP )_) kits_NNS for_IN
          the_DT HIV-_NNP 1_CD p_NN 24_CD antigen_NN were_VBD from_IN Beckman_NNP Coulter_NNP ,_, Inc_NNP ._. ,_,
          Miami_NNP ,_, FL_NNP ._. The_DT tyrosine-sulfated_JJ peptide_NN from_IN CCR_NNP 5_CD [_NN 25_CD ]_NN
          ;_: {_( S-_NNP peptide_NN ;_: MDYQVSSPI_NNP 
          Y_NNP DIN_NNP 
          Y_NNP YTSEPSQK_NNP ;_: (_( 
          Y_NNP =_SYM sulfotyrosine_NN )_) }_) was_VBD from_IN American_NNP
          Peptide_NNP ,_, Sunnyvale_NNP ,_, CA_NNP ._. The_DT corresponding_JJ control_NN peptide_NN
          with_IN tyrosines_NNS instead_RB of_IN sulfotyrosines_NNS ,_, and_CC N_NNP 36_CD
          (_( SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARVL_NNP )_) and_CC C_NNP 34_CD
          (_( WIEWDREINNYTSIIYSLIEESQNQQEKNEQELL_NNP )_) peptide_NN constituents_NNS
          of_IN the_DT gp_NN 41_CD core_NN [_NN 20_CD 21_CD ]_NN of_IN HIV-_NNP 1_CD BaL_NNP were_VBD from_IN
          AnaSpec_NNP ,_, Inc_NNP ._. ,_, San_NNP Jose_NNP ,_, CA_NNP ._. CAP_NNP was_VBD a_DT gift_NN from_IN Eastman_NNP
          Chemical_NNP Company_NNP ,_, Kingsport_NNP ,_, TN_NNP ._. H_NNP 9_CD cells_NNS chronically_RB
          infected_VBN with_IN HIV-_NNP 1_CD IIIB_NNP ,_, and_CC PM_NNP 1_CD cells_NNS were_VBD obtained_VBN
          from_IN the_DT AIDS_NNP Research_NNP and_CC Reference_NNP Reagent_NNP Program_NN
          contributed_VBN by_IN Drs_NNP ._. R_NN ._. Gallo_NNP ,_, P_NN ._. Lusso_NNP and_CC M_NNP ._. Reitz_NNP ,_,
          respectively_RB ._.
        
        
          Inhibition_NNP of_IN HIV-_NNP 1_CD infection_NN
          HIV-_NNP 1_CD IIIB_NNP (_( 100_CD TCID_NNP 
          50_CD )_) in_IN the_DT presence_NN or_CC absence_NN of_IN
          graded_JJ concentrations_NNS of_IN virus_NN inhibitors_NNS ,_, CAP_NNP and_CC sCD_NN 4_CD ,_,
          respectively_RB ,_, in_IN RPMI-_NNP 1640_CD medium_NN containing_VBG 10_CD %_NN fetal_JJ
          bovine_JJ serum_NN (_( FBS_NNP )_) were_VBD mixed_VBN with_IN MT-_NNP 2_CD cells_NNS (_( 10_CD
          4_CD cells_NNS /_NN well_RB )_) and_CC placed_VBN into_IN 96_CD -_: well_RB polystyrene_NN plates_NNS ._.
          The_DT mixtures_NNS were_VBD incubated_JJ at_IN 37_CD °_NN C_NNP overnight_JJ ._. On_IN the_DT 2_CD
          ndday_NN ,_, culture_NN supernatants_NNS were_VBD removed_VBN from_IN each_DT well_RB
          and_CC fresh_JJ medium_NN was_VBD added_VBN ._. On_IN the_DT 4_CD thday_NN ,_, culture_NN
          supernatants_NNS were_VBD collected_VBN and_CC tested_VBN for_IN p_NN 24_CD antigen_NN by_IN
          ELISA_NNP ._. Similar_JJ experiments_NNS were_VBD done_VBN with_IN HIV-_NNP 1_CD BaL_NNP (_( 2_CD ._. 5_LS
          ×_NN 10_CD 5_CD virus_NN particles_NNS )_) ,_, except_IN that_DT PM_NNP 1_CD cells_NNS [_NN 26_CD ]_NN were_VBD
          used_VBN instead_RB of_IN MT-_NNP 2_CD cells_NNS ._.
          The_DT inhibitory_NN activity_NN of_IN CAP_NNP and_CC sCD_NN 4_CD in_IN
          combination_NN ,_, against_IN HIV-_NNP 1_CD infection_NN was_VBD determined_VBN as_IN
          described_VBN above_IN ._. The_DT CAP_NNP :_: sCD_NN 4_CD weight_NN ratios_NNS in_IN the_DT
          combinations_NNS were_VBD 10_CD :_: 1_CD and_CC 2_CD :_: 1_CD for_IN HIV-_NNP 1_CD IIIB_NNP and_CC HIV-_NNP 1_CD
          BaL_NNP ,_, respectively_RB ._. The_DT 50_CD %_NN inhibitory_NN concentrations_NNS (_( IC_NNP 
          50_CD )_) and_CC the_DT combination_NN index_NN values_NNS
          (_( CI_NNP )_) were_VBD calculated_VBN as_RB previously_RB described_VBD [_NN 27_CD ]_NN using_VBG
          a_DT computer_NN program_NN (_( CalcuSyn_NNP )_) kindly_RB provided_VBN by_IN Dr_NNP ._. T_NN ._.
          C_NNP ._. Chou_NNP (_( Sloan-_NNP Kettering_NNP Cancer_NNP Center_NNP ,_, New_NNP York_NNP )_) ._. A_DT CI_NNP
          value_NN <_NN 1_CD indicates_VBZ synergy_NN and_CC that_IN of_IN >_NN 1_CD
          indicates_VBZ antagonism_NN ._. The_DT compound_NN dose_NN reductions_NNS were_VBD
          calculated_VBN based_VBN on_IN the_DT IC_NNP 
          50_CD value_NN for_IN CAP_NNP and_CC sCD_NN 4_CD used_VBN alone_RB
          or_CC in_IN combination_NN [_NN 27_CD ]_NN ._.
          To_TO measure_VB the_DT virucidal_NN activity_NN of_IN CAP_NNP /_NN sCD_NN 4_CD
          combinations_NNS ,_, treated_VBN and_CC untreated_JJ purified_JJ HIV-_NNP 1_CD IIIB_NNP
          (_( 3_CD ._. 4_LS ×_NN 10_CD 8_CD virus_NN particles_NNS )_) (_( unlike_IN in_IN the_DT experiments_NNS
          described_VBD in_IN an_DT earlier_JJR report_NN [_NN 8_CD ]_NN where_WRB infectious_JJ
          tissue_NN culture_NN medium_NN was_VBD used_VBN instead_RB )_) ,_, were_VBD serially_RB
          diluted_VBN 2_CD -_: to_TO 256_CD -_: fold_VB in_IN RPMI-_NNP 1640_CD medium_NN containing_VBG 10_CD %_NN
          FBS_NNP ,_, mixed_VBN with_IN MT-_NNP 2_CD cells_NNS and_CC placed_VBN into_IN 96_CD -_: well_RB
          polystyrene_NN plates_NNS ._. Virus_NNP replication_NN was_VBD monitored_VBN by_IN
          measuring_VBG p_NN 24_CD antigen_NN as_IN described_VBN above_IN ._. Similar_JJ
          experiments_NNS were_VBD done_VBN with_IN HIV-_NNP 1_CD BaL_NNP (_( 2_CD ._. 5_LS ×_NN 10_CD 8_CD virus_NN
          particles_NNS )_) ,_, except_IN that_DT PM_NNP 1_CD cells_NNS were_VBD used_VBN instead_RB of_IN
          MT-_NNP 2_CD cells_NNS ._. The_DT percentage_NN of_IN residual_JJ infectivity_NN after_IN
          CAP_NNP /_NN sCD_NN 4_CD treatment_NN was_VBD calculated_VBN from_IN calibration_NN curves_NNS
          relating_VBG absorbance_NN to_TO virus_NN dilutions_NNS of_IN untreated_JJ
          viruses_NNS ._.
        
        
          Enzyme-linked_NNP immunosorbent_NN assays_NNS (_( ELISA_NNP )_)
          For_IN virus_NN capture_NN assays_NNS ,_, wells_NNS of_IN 96_CD -_: well_RB polystyrene_NN
          plates_NNS (_( Immulon_NNP II_NNP ;_: Dynatech_NNP Laboratories_NNPS Inc_NNP ._. ,_,
          Chantilly_NNP ,_, VA_NNP )_) were_VBD coated_VBN either_CC with_IN CAP_NNP (_( 1_CD μg_NN /_NN well_RB )_) ._.
          or_CC with_IN mAb_NN NC-_NNP 1_CD [_NN 20_CD 21_CD ]_NN ._. For_IN coating_NN with_IN CAP_NNP ,_, a_DT
          solution_NN of_IN CAP_NNP (_( 100_CD μl_NN ;_: 10_CD μg_NN /_NN ml_NN in_IN 0_CD ._. 05_CD M_NNP acetate_NN pH_NN
          6_CD ._. 0_CD )_) was_VBD added_VBN to_TO the_DT wells_NNS ._. After_IN incubation_NN overnight_JJ
          at_IN 4_CD °_NN C_NNP ,_, the_DT wells_NNS were_VBD washed_VBN and_CC postcoated_JJ for_IN 1_CD h_NN at_IN
          20_CD °_NN C_NNP with_IN bovine_JJ serum_NN albumin_NN (_( BSA_NNP )_) and_CC gelatin_NN (_( 1_CD and_CC
          0_CD ._. 1_CD mg_NN /_NN ml_NN in_IN 0_CD ._. 05_CD M_NNP acetate_NN pH_NN 6_CD ._. 0_CD )_) ._. For_IN coating_NN with_IN
          antibodies_NNS ,_, wells_NNS were_VBD first_JJ coated_VBN with_IN protein_NN A_DT /_NN G_NNP (_( 1_CD
          μg_NN /_NN well_RB )_) in_IN 0_CD ._. 1_CD M_NNP Tris_NNP buffer_NN ,_, pH_NN 8_CD ._. 8_CD for_IN 2_CD h_NN at_IN 20_CD °_NN C_NNP ,_,
          followed_VBN by_IN mAb_NN NC-_NNP 1_CD or_CC normal_JJ mouse_NN IgG_NNP (_( =_SYM control_NN
          wells_NNS )_) {_( 1_CD μg_NN /_NN well_RB ;_: diluted_VBN in_IN phosphate_NN buffered_JJ saline_NN
          (_( PBS_NNP )_) }_) for_IN 1_CD h_NN at_IN 20_CD °_NN C_NNP ._. Coating_NNP with_IN the_DT N_NNP 36_CD /_NN C_NNP 34_CD peptide_NN
          complexes_NNS (_( 0_CD ._. 01_CD to_TO 10_CD μM_NN )_) was_VBD done_VBN under_IN conditions_NNS
          described_VBD for_IN protein_NN A_DT /_NN G_NNP ._. Subsequently_NNP the_DT wells_NNS were_VBD
          washed_VBN and_CC postcoated_JJ with_IN BSA_NNP and_CC gelatin_NN as_IN described_VBN
          above_IN ,_, except_IN that_IN these_DT proteins_NNS were_VBD dissolved_VBN in_IN 0_CD ._. 14_CD
          M_NNP NaCl_NNP ,_, 0_CD ._. 01_CD M_NNP Tris_NNP ,_, pH_NN 7_CD ._. 0_CD (_( TS_NNP )_) ._. Chicken_NN serum_NN (_( 10_CD %_NN )_) in_IN
          PBS_NNP (_( Ch-_NNP PBS_NNP )_) was_VBD used_VBN instead_RB in_IN experiments_NNS with_IN HIV-_NNP 1_CD
          BaL_NNP to_TO suppress_VB binding_VBG of_IN this_DT virus_NN to_TO control_VB wells_NNS ._.
          The_DT wells_NNS were_VBD washed_VBN with_IN TS_NNP and_CC stored_VBD at_IN 4_CD °_NN C_NNP ._. HIV-_NNP 1_CD
          virus_NN particles_NNS suspended_VBN in_IN diluents_NNS and_CC treated_VBN as_IN
          indicated_VBN in_IN legends_NNS to_TO Figs_NNP ._. 2_LS ,_, 3_CD ,_, 5_CD were_VBD added_VBN to_TO the_DT
          wells_NNS for_IN 5_CD h_NN at_IN 4_CD °_NN C_NNP ._. Subsequently_NNP the_DT wells_NNS were_VBD washed_VBN
          10_CD ×_NN with_IN ice_NN cold_JJ PBS_NNP or_CC 1_CD :_: 50_CD anti-p_JJ 24_CD mAb_NN in_IN Ch-_NNP PBS_NNP for_IN
          HIV-_NNP 1_CD BaL_NNP to_TO minimize_VB the_DT contribution_NN of_IN p_NN 24_CD antigen_NN not_RB
          associated_VBN with_IN virus_NN particles_NNS to_TO absorbance_NN readings_NNS
          corresponding_JJ to_TO p_NN 24_CD antigen_NN released_VBN from_IN detergent_NN
          treated_VBD virus_NN ._. The_DT washed_VBN wells_NNS with_IN bound_VBN virus_NN
          particles_NNS were_VBD then_RB treated_VBN with_IN lysis_NNS buffer_NN (_( 1_CD %_NN Nonidet_NNP
          P_NN 40_CD {_( NP_NNP 40_CD }_) ,_, 100_CD μg_NN /_NN ml_NN BSA_NNP in_IN PBS_NNP )_) for_IN 30_CD min_NN at_IN 37_CD °_NN C_NNP ._. The_DT
          supernatants_NNS were_VBD removed_VBN and_CC tested_VBN for_IN p_NN 24_CD antigen_NN
          using_VBG ELISA_NNP kits_NNS from_IN Beckman_NNP Coulter_NNP ,_, Inc_NNP ._. following_VBG the_DT
          manufacturer_NN 's_POS protocol_NN ._.
          To_TO measure_VB the_DT binding_JJ of_IN biotinyl-s_JJ CD_NNP 4_CD and_CC
          biotinyl-gp_JJ 120_CD (_( in_IN the_DT presence_NN and_CC absence_NN of_IN sCD_NN 4_LS )_) ,_,
          respectively_RB ,_, to_TO CAP_NNP ,_, the_DT biotinylated_JJ proteins_NNS were_VBD
          added_VBN to_TO CAP_NNP and_CC control_VB postcoated_JJ wells_NNS without_IN CAP_NNP ,_,
          respectively_RB ,_, at_IN dilutions_NNS shown_VBN in_IN Fig_NNP ._. 1_LS ._. The_DT binding_VBG
          of_IN these_DT biotinylated_JJ proteins_NNS to_TO the_DT wells_NNS ,_, after_IN
          washing_VBG with_IN TS_NNP ,_, was_VBD determined_VBN by_IN adding_VBG
          HRP-streptavidin_NNP (_( 1_CD μg_NN /_NN ml_NN )_) in_IN TS_NNP containing_VBG 0_CD ._. 25_CD %_NN gelatin_NN
          and_CC 0_CD ._. 05_CD %_NN Tween_NNP 20_CD for_IN 30_CD min_NN at_IN 37_CD °_NN C_NNP ._. The_DT wells_NNS were_VBD
          washed_VBN and_CC bound_VBN HRP_NNP was_VBD detected_VBN using_VBG the_DT test_NN kit_NN from_IN
          Kirkegaard_NNP &_CC Perry_NNP following_VBG the_DT manufacturer_NN 's_POS
          protocol_NN ,_, and_CC the_DT absorbance_NN was_VBD read_VBN at_IN 450_CD nm_NN ._.
          The_DT sandwich_NN ELISA_NNP for_IN the_DT gp_NN 41_CD six-helix_JJ bundle_NN was_VBD
          performed_VBN as_IN described_VBN [_NN 21_CD ]_NN ._. Treated_NNP and_CC control_NN virus_NN
          preparations_NNS were_VBD incubated_JJ with_IN lysis_NNS buffer_NN for_IN 30_CD min_NN
          at_IN 20_CD °_NN C_NNP and_CC then_RB added_VBD to_TO wells_NNS coated_VBN with_IN rabbit_NN
          polyclonal_NN antibodies_NNS to_TO the_DT gp_NN 41_CD core_NN ._. In_IN control_NN
          experiments_NNS ,_, CAP_NNP alone_RB (_( 5_CD mg_NN /_NN ml_NN in_IN lysis_NNS buffer_NN )_) was_VBD
          added_VBN to_TO the_DT wells_NNS ._. After_IN incubation_NN at_IN 4_CD °_NN C_NNP overnight_JJ ,_,
          binding_JJ of_IN six-helix_JJ bundles_NNS was_VBD determined_VBN from_IN
          subsequent_JJ binding_JJ of_IN mAb_NN NC-_NNP 1_CD ,_, which_WDT was_VBD added_VBN at_IN 1_CD
          μg_NN /_NN ml_NN in_IN PBS_NNP /_NN 1_CD %_NN BSA_NNP /_NN 1_CD %_NN gelatin_NN (_( 100_CD μl_NN /_NN well_RB )_) for_IN 1_CD h_NN at_IN
          37_CD °_NN C_NNP ._. Subsequently_NNP the_DT wells_NNS were_VBD washed_VBN three_CD times_NNS with_IN
          PBS_NNP /_NN 0_CD ._. 05_CD %_NN Tween_NNP 20_CD and_CC biotin_NN labeled_VBD anti-mouse_JJ IgG_NNP (_( 100_CD
          μl_NN /_NN well_RB ;_: 125_CD ng_NN /_NN ml_NN diluted_VBN in_IN PBS_NNP containing_VBG 1_CD %_NN dry_JJ
          fat-free_JJ milk_NN )_) was_VBD added_VBN ._. After_IN incubation_NN for_IN 1_CD h_NN at_IN
          37_CD °_NN C_NNP ,_, the_DT wells_NNS were_VBD washed_VBN as_IN described_VBN above_IN and_CC
          HRP-streptavidin_NNP (_( 125_CD ng_NN /_NN ml_NN in_IN PBS_NNP containing_VBG 10_CD %_NN goat_NN
          serum_NN ;_: 100_CD μl_NN /_NN well_RB )_) was_VBD added_VBN ._. After_IN incubation_NN for_IN 1_CD h_NN
          at_IN 37_CD °_NN C_NNP ,_, the_DT wells_NNS were_VBD washed_VBN six_CD times_NNS with_IN PBS_NNP /_NN 0_CD ._. 05_CD %_NN
          Tween_NNP 20_CD ._. HRP_NNP was_VBD quantitated_JJ as_IN described_VBN above_IN ._.
          To_TO exclude_VB the_DT remote_JJ possibility_NN that_DT mAb_NN NC-_NNP 1_CD
          reacted_VBD with_IN CAP_NNP ,_, serial_JJ two-fold_JJ dilutions_NNS (_( 0_CD ._. 25_CD to_TO 8_CD
          μg_NN /_NN ml_NN )_) of_IN the_DT mAb_NN and_CC of_IN control_NN mouse_NN IgG_NNP ,_, respectively_RB
          (_( each_DT at_IN 16_CD μg_NN /_NN ml_NN in_IN PBS-BG_NNP )_) were_VBD added_VBN to_TO CAP_NNP coated_JJ or_CC
          CAP-gp_NNP 120_CD coated_JJ wells_NNS for_IN 1_CD h_NN at_IN 37_CD °_NN C_NNP ._. The_DT wells_NNS were_VBD
          washed_VBN and_CC bound_VBN IgG_NNP was_VBD quantitated_JJ as_IN described_VBN above_IN
          for_IN the_DT sandwich_NN ELISA_NNP ._. CAP-gp_NNP 120_CD wells_NNS were_VBD prepared_VBN by_IN
          coating_NN first_RB with_IN HIV-_NNP 1_CD IIIB_NNP gp_NN 120_CD under_IN conditions_NNS
          described_VBD above_IN for_IN protein_NN A_DT /_NN G_NNP ,_, except_IN that_IN the_DT pH_NN was_VBD
          8_CD ._. 0_CD instead_RB of_IN 8_CD ._. 8_CD ._. Subsequently_RB ,_, CAP_NNP was_VBD added_VBN to_TO the_DT
          wells_NNS as_IN described_VBN above_IN ._. In_IN control_NN experiments_NNS ,_, serial_NN
          dilutions_NNS (_( 1_CD /_NN 200_CD to_TO 1_CD /_NN 1_CD ,_, 600_CD )_) of_IN rabbit_NN anti-phthalate_JJ
          antiserum_NN and_CC of_IN normal_JJ rabbit_NN serum_NN ,_, respectively_RB (_( each_DT
          diluted_VBN 100_CD -_: fold_VB in_IN PBS-BG_NNP )_) were_VBD added_VBN to_TO the_DT wells_NNS ._.
          Bound_NNP rabbit_NN IgG_NNP was_VBD quantitated_JJ using_VBG biotinylated_JJ goat_NN
          anti-rabbit_JJ IgG_NNP ._.
        
        
          Shedding_NNP of_IN gp_NN 120_CD from_IN virus_NN particles_NNS
          Preparations_NNP of_IN purified_JJ HIV-_NNP 1_CD IIIB_NNP and_CC BaL_NNP ,_,
          respectively_RB ,_, were_VBD incubated_JJ for_IN 5_CD min_NN at_IN 37_CD °_NN C_NNP in_IN the_DT
          presence_NN or_CC absence_NN of_IN CAP_NNP (_( final_JJ concentration_NN 5_CD mg_NN /_NN ml_NN )_) ._.
          Control_NN preparations_NNS were_VBD not_RB exposed_VBN to_TO 37_CD °_NN C_NNP ._. Virus_NNP
          particles_NNS and_CC released_VBN gp_NN 120_CD were_VBD separated_VBN by_IN
          centrifugation_NN as_IN described_VBN [_NN 28_CD ]_NN ._. The_DT virus_NN containing_VBG
          pellets_NNS and_CC supernatant_NN fluids_NNS were_VBD assayed_JJ by_IN an_DT ELISA_NNP
          allowing_VBG gp_NN 120_CD determination_NN in_IN the_DT presence_NN of_IN CAP_NNP ._.
          Wells_NNP of_IN polystyrene_NN plates_NNS were_VBD coated_VBN with_IN protein_NN A_DT /_NN G_NNP ,_,
          followed_VBN by_IN polyclonal_NN rabbit_NN anti-gp_JJ 120_CD (_( diluted_VBN
          500_CD -_: fold_VB )_) under_IN conditions_NNS described_VBD above_IN for_IN virus_NN
          capture_NN assays_NNS ._. Serial_JJ twofold_NN dilutions_NNS in_IN PBS-BG_NNP of_IN
          preparations_NNS containing_VBG gp_NN 120_CD were_VBD added_VBN to_TO the_DT wells_NNS ._.
          After_IN 4_CD h_NN at_IN 20_CD °_NN C_NNP ,_, the_DT wells_NNS were_VBD washed_VBN and_CC bound_VBN gp_NN 120_CD
          was_VBD detected_VBN by_IN addition_NN of_IN biotinyl-s_JJ CD_NNP 4_CD (_( 1_CD μg_NN )_) followed_VBN
          by_IN HRP-streptavidin_NNP as_IN described_VBN above_IN ._. The_DT amount_NN of_IN
          gp_NN 120_CD in_IN the_DT virus_NN pellets_NNS and_CC the_DT supernatant_NN fluids_NNS was_VBD
          calculated_VBN from_IN calibration_NN curves_NNS relating_VBG absorbance_NN
          readings_NNS to_TO gp_NN 120_CD dilutions_NNS ._. All_DT determinations_NNS were_VBD done_VBN
          in_IN triplicate_NN ._.
        
        
          Molecular_NNP modeling_NN :_: Docking_NNP of_IN CAP_NNP on_IN the_DT gp_NN 41_CD core_NN
          structure_NN
          The_DT acetylated_JJ and_CC phthaloylated_JJ cellotetraose_NN unit_NN
          (_( CTAP_NNP )_) composed_VBN of_IN four_CD 1_CD ,_, 4_CD -_: linked_VBN β-_NN D-_NNP glucose_NN units_NNS ,_,
          which_WDT is_VBZ a_DT representative_NN part_NN of_IN CAP_NNP was_VBD created_VBN in_IN
          Quanta_NNP 2000_CD [_NN 29_CD ]_NN as_IN described_VBN before_IN [_NN 8_CD ]_NN ._. CTAP_NNP was_VBD
          minimized_VBN by_IN the_DT steepest_JJS descent_NN method_NN followed_VBN by_IN the_DT
          adopted_VBN basis_NN Newton-_NNP Raphson_NNP (_( ABNR_NNP )_) method_NN ._. The_DT energy_NN
          difference_NN of_IN 0_CD ._. 05_CD Kcal_NNP /_NN mol_NN between_IN two_CD successive_JJ
          structures_NNS during_IN both_DT minimization_NN steps_NNS was_VBD used_VBN as_IN the_DT
          termination_NN criterion_NN ._.
          The_DT docking_VBG simulations_NNS of_IN CTAP_NNP were_VBD performed_VBN using_VBG
          the_DT DockVision_NNP program_NN [_NN 30_CD ]_NN on_IN the_DT entire_JJ surface_NN of_IN
          the_DT gp_NN 41_CD core_NN structure_NN {_( The_DT X-_NNP ray_NN crystal_NN structure_NN of_IN
          the_DT gp_NN 41_CD core_NN ,_, 1_CD aik_NN ,_, was_VBD retrieved_VBN from_IN the_DT protein_NN
          databank_NN http_NN :_: /_NN /_NN www_NN ._. rcsb_NN ._. org_NN }_) ._. A_DT grid_NN box_NN (_( 125_CD ×_NN 125_CD Å_NN ×_NN
          125_CD Å_NN )_) was_VBD created_VBN to_TO cover_VB the_DT entire_JJ gp_NN 41_CD core_NN surface_NN
          for_IN CTAP_NNP to_TO dock_NN ._. The_DT default_NN forcefield_NN (_( Research_NNP
          Potential_JJ Function_NNP )_) was_VBD used_VBN to_TO perform_VB 1000_CD Monte_NNP Carlo_NNP
          runs_VBZ for_IN docking_VBG simulations_NNS ._. Both_DT CTAP_NNP and_CC the_DT gp_NN 41_CD core_NN
          structure_NN were_VBD kept_VBN rigid_JJ during_IN docking_VBG ._. Intermolecular_NNP
          energy_NN criteria_NNS were_VBD used_VBN to_TO select_VB the_DT lowest_JJS energy_NN
          docked_JJ CTAP_NNP ._.
        
        
          Electrostatic_NNP potential_JJ maps_NNS of_IN gp_NN 120_CD and_CC the_DT
          gp_NN 120_CD -_: CD_NNP 4_CD complex_JJ
          Electrostatic_NNP potentials_NNS were_VBD calculated_VBN using_VBG a_DT
          Poisson-_NNP Boltzmann_NNP solver_NN included_VBN in_IN the_DT GRASP_NNP program_NN [_NN
          31_CD ]_NN ._. All_DT default_NN parameters_NNS were_VBD used_VBN ._. The_DT
          electrostatic_JJ potential_JJ maps_NNS are_VBP shown_VBN on_IN the_DT accessible_JJ
          surface_NN of_IN gp_NN 120_CD and_CC the_DT gp_NN 120_CD -_: CD_NNP 4_CD complex_JJ ._.
        
      
      
        Results_NNS
        
          Enhancement_NNP of_IN CAP-HIV-_NNP 1_CD binding_JJ by_IN CD_NNP 4_CD
          Earlier_JJR studies_NNS [_NN 8_CD ]_NN indicated_VBD that_IN CAP_NNP binding_VBG to_TO
          the_DT envelope_NN glycoprotein_NN gp_NN 120_CD and_CC to_TO HIV-_NNP 1_CD virus_NN
          particles_NNS ,_, respectively_RB ,_, did_VBD not_RB interfere_VB with_IN their_PRP$
          subsequent_JJ association_NN with_IN sCD_NN 4_CD ._. Thus_RB ,_, it_PRP would_MD be_VB
          expected_VBN that_IN CAP_NNP would_MD not_RB inhibit_VB the_DT attachment_NN of_IN
          HIV-_NNP 1_CD to_TO target_VB cells_NNS and_CC would_MD block_VB only_RB subsequent_JJ
          steps_NNS obligatory_JJ for_IN HIV-_NNP 1_CD infection_NN initiated_VBN by_IN
          engagement_NN of_IN CXCR_NNP 4_CD and_CC CCR_NNP 5_CD coreceptors_NNS ,_, respectively_RB ._.
          The_DT latter_JJ event_NN was_VBD shown_VBN to_TO be_VB blocked_VBN by_IN CAP_NNP [_NN 8_CD ]_NN and_CC
          has_VBZ been_VBN considered_VBN the_DT basis_NN for_IN the_DT virus_NN inhibitory_NN
          and_CC virus_NN inactivating_VBG properties_NNS of_IN CAP_NNP at_IN neutral_JJ pH_NN ._.
          However_RB ,_, it_PRP has_VBZ not_RB been_VBN determined_VBN whether_IN or_CC not_RB
          occupancy_NN of_IN CD_NNP 4_CD binding_JJ sites_NNS within_IN gp_NN 120_CD would_MD affect_VB
          subsequent_JJ interactions_NNS with_IN CAP_NNP ._. To_TO answer_VB this_DT
          question_NN ,_, the_DT binding_JJ of_IN gp_NN 120_CD and_CC gp_NN 120_CD -_: sCD_NN 4_CD complexes_NNS ,_,
          respectively_RB ,_, to_TO immobilized_JJ CAP_NNP was_VBD studied_VBN ._. Results_NNS
          shown_VBN in_IN Fig_NNP ._. 1_LS indicated_VBD that_DT sCD_NN 4_CD enhanced_JJ gp_NN 120_CD -_: CAP_NNP
          binding_JJ ._. Maximum_NNP enhancement_NN was_VBD observed_VBN at_IN sCD_NN 4_CD /_NN gp_NN 120_CD
          weight_NN ratios_NNS of_IN ≥_NN 0_CD ._. 6_CD (_( Fig_NNP ._. 1_LS insert_VB )_) ,_, corresponding_JJ to_TO a_DT
          molar_NN ratio_NN of_IN ≥_NN 1_CD ._. 2_CD [_NN 32_CD ]_NN ,_, in_IN agreement_NN with_IN the_DT
          observation_NN that_DT gp_NN 120_CD -_: CD_NNP 4_CD complexes_NNS consist_VBP of_IN one_CD
          molecule_NN each_DT of_IN CD_NNP 4_CD and_CC gp_NN 120_CD [_NN 16_CD ]_NN ._. Biotinyl-s_NNP CD_NNP 4_CD in_IN
          the_DT absence_NN of_IN gp_NN 120_CD did_VBD not_RB bind_NN to_TO CAP_NNP ._. Similarly_RB ,_,
          pretreatment_NN of_IN HIV-_NNP 1_CD with_IN sCD_NN 4_CD resulted_VBD in_IN subsequent_JJ
          increased_VBN binding_JJ of_IN virus_NN with_IN CAP_NNP ,_, the_DT effect_NN being_VBG
          much_RB more_RBR pronounced_JJ with_IN HIV-_NNP 1_CD BaL_NNP in_IN comparison_NN with_IN
          HIV-_NNP 1_CD IIIB_NNP (_( Fig_NNP ._. 2_LS )_) ._.
        
        
          Synergism_NNP between_IN CAP_NNP and_CC sCD_NN 4_CD in_IN inhibiting_VBG HIV-_NNP 1_CD
          infection_NN
          Since_IN HIV-_NNP 1_CD can_MD bind_NN CAP_NNP and_CC sCD_NN 4_CD simultaneously_RB ,_, and_CC
          the_DT binding_JJ of_IN CAP_NNP is_VBZ enhanced_VBN in_IN the_DT presence_NN of_IN sCD_NN 4_CD ,_,
          it_PRP was_VBD of_IN interest_NN to_TO determine_VB whether_IN these_DT two_CD ligands_NNS
          act_VBP on_IN HIV-_NNP 1_CD cooperatively_RB ,_, resulting_VBG in_IN synergism_NN of_IN
          their_PRP$ antiviral_JJ effects_NNS ._. This_DT indeed_RB was_VBD observed_VBN (_( Table_NNP
          1_CD and_CC 2_CD ,_, Fig_NNP ._. 3_LS )_) ._. CAP_NNP and_CC sCD_NN 4_CD synergistically_RB inhibited_VBD
          infection_NN by_IN HIV-_NNP 1_CD IIIB_NNP (_( Table_NNP 1_LS )_) and_CC HIV-_NNP 1_CD BaL_NNP (_( Table_NNP
          2_LS )_) ._. A_DT similar_JJ synergism_NN was_VBD observed_VBN for_IN virucidal_NN
          activity_NN against_IN HIV-_NNP 1_CD IIIB_NNP (_( Fig_NNP ._. 3_LS )_) but_CC only_RB additive_JJ
          effects_NNS were_VBD found_VBN for_IN HIV-_NNP 1_CD BaL_NNP (_( in_IN the_DT absence_NN of_IN sCD_NN 4_CD ,_,
          ED_NNP 
          50_CD for_IN CAP_NNP =_SYM 1_CD ._. 49_CD ±_NN 0_CD ._. 38_CD mg_NN /_NN ml_NN ;_: in_IN the_DT
          presence_NN of_IN sCD_NN 4_CD [_NN 100_CD μg_NN /_NN ml_NN ]_NN ,_, which_WDT caused_VBD an_DT 1_CD ._. 85_CD -_: fold_VB
          decrease_NN of_IN infectivity_NN ,_, ED_NNP 
          50_CD =_SYM 1_CD ._. 39_CD ±_NN 0_CD ._. 18_CD mg_NN /_NN ml_NN for_IN residual_JJ
          infectivity_NN )_) ._.
        
        
          Treatment_NNP of_IN HIV-_NNP 1_CD with_IN CAP_NNP leads_VBZ to_TO induction_NN of_IN
          gp_NN 41_CD six-helix_JJ bundles_NNS
          Earlier_JJR studies_NNS [_NN 8_CD ]_NN ,_, in_IN which_WDT the_DT binding_JJ of_IN CAP_NNP
          treated_VBD and_CC untreated_JJ virus_NN with_IN antibodies_NNS specific_JJ for_IN
          distinct_JJ regions_NNS on_IN the_DT envelope_NN glycoproteins_NNS gp_NN 120_CD and_CC
          gp_NN 41_CD was_VBD studied_VBN ,_, indicated_VBD that_IN CAP_NNP had_VBD either_CC no_DT effect_NN
          or_CC caused_VBN decreased_VBD binding_JJ with_IN antibodies_NNS against_IN
          several_JJ peptides_NNS from_IN gp_NN 120_CD but_CC only_RB against_IN a_DT single_JJ
          peptide_NN ,_, 557_CD -_: 586_CD ,_, from_IN gp_NN 41_CD (_( see_VB Discussion_NNP )_) ._. It_PRP was_VBD
          intended_VBN to_TO expand_VB these_DT studies_NNS to_TO mAb_NN NC-_NNP 1_CD ,_, specific_JJ
          for_IN the_DT gp_NN 41_CD six-helix_JJ bundle_NN [_NN 20_CD ]_NN ._. Results_NNS of_IN
          preliminary_JJ studies_NNS indicated_VBD that_IN CAP_NNP did_VBD not_RB interfere_VB
          with_IN the_DT six-helix_JJ bundle_NN formation_NN from_IN constituent_NN
          peptides_NNS derived_VBN from_IN near_IN the_DT N-_NNP and_CC C-_NNP terminus_JJ of_IN the_DT
          gp_NN 41_CD ectodomain_NN [_NN 20_CD ]_NN ;_: (_( own_JJ unpublished_JJ data_NNS )_) ._.
          Surprisingly_RB ,_, and_CC unlike_IN with_IN mAb_NN 2_CD F_NN 5_CD [_NN 8_CD ]_NN specific_JJ for_IN
          the_DT C-_NNP terminal_NN region_NN of_IN the_DT gp_NN 41_CD ectodomain_NN [_NN 33_CD ]_NN ,_, CAP_NNP
          treatment_NN enhanced_VBD the_DT binding_VBG of_IN both_DT HIV-_NNP 1_CD IIIB_NNP and_CC
          HIV-_NNP 1_CD BaL_NNP to_TO mAb_NN NC-_NNP 1_CD ,_, reacting_VBG with_IN gp_NN 41_CD six-helix_JJ
          bundles_NNS from_IN both_DT HIV-_NNP 1_CD IIIB_NNP and_CC BaL_NNP (_( Fig_NNP ._. 4_LS )_) ,_, suggesting_VBG
          the_DT formation_NN of_IN these_DT structures_NNS within_IN virus_NN particles_NNS
          as_IN a_DT result_NN of_IN CAP_NNP treatment_NN (_( Fig_NNP ._. 5_LS )_) ._. Treatment_NNP with_IN
          both_DT CAP_NNP and_CC sCD_NN 4_CD further_RBR enhanced_VBD the_DT expression_NN of_IN the_DT
          six-helix_JJ bundles_NNS in_IN the_DT case_NN of_IN HIV-_NNP 1_CD Bal_NNP (_( Fig_NNP 5_CD B_NNP )_) ,_, but_CC
          not_RB in_IN the_DT case_NN of_IN HIV-_NNP 1_CD IIIB_NNP (_( Fig_NNP 5_CD A_DT )_) ._. sCD_NN 4_CD alone_RB was_VBD
          less_RBR effective_JJ in_IN enhancing_VBG the_DT expression_NN of_IN the_DT
          six-helix_JJ bundles_NNS ._. Treatment_NNP of_IN neither_DT recombinant_JJ gp_NN 160_CD
          or_CC the_DT gp_NN 41_CD C-_NNP peptide_NN with_IN CAP_NNP resulted_VBD in_IN generation_NN of_IN
          epitopes_NNS recognized_VBN by_IN mAb_NN NC-_NNP 1_CD (_( data_NNS not_RB shown_VBN )_) ._.
          To_TO exclude_VB the_DT remote_JJ possibility_NN that_DT mAb_NN NC-_NNP 1_CD
          reacted_VBD with_IN CAP_NNP or_CC protein-bound_JJ CAP_NNP ,_, and_CC that_IN this_DT ,_,
          rather_RB than_IN binding_JJ to_TO six-helix_JJ bundles_NNS ,_, would_MD lead_VB to_TO
          results_NNS shown_VBN in_IN Fig_NNP ._. 5_LS ,_, the_DT binding_VBG of_IN the_DT mAb_NN to_TO CAP_NNP
          coated_JJ wells_NNS was_VBD investigated_VBN ._. No_DT significant_JJ binding_JJ of_IN
          mAb_NN NC-_NNP 1_CD and_CC of_IN control_NN mouse_NN IgG_NNP ,_, respectively_RB ,_, to_TO wells_NNS
          coated_VBN by_IN CAP_NNP directly_RB or_CC to_TO CAP_NNP bound_VBN to_TO HIV-_NNP 1_CD IIIB_NNP
          gp_NN 120_CD was_VBD observed_VBN ._. On_IN the_DT other_JJ hand_NN ,_, anti-phthalate_JJ
          antibodies_NNS reacted_VBD with_IN both_DT forms_NNS of_IN immobilized_JJ CAP_NNP
          (_( Fig_NNP ._. 6_CD )_) ._. These_DT results_NNS support_VBP the_DT conclusions_NNS from_IN
          results_NNS in_IN Fig_NNP ._. 5_LS ._.
          Engagement_NNP of_IN the_DT gp_NN 120_CD coreceptor_NN binding_JJ site_NN with_IN a_DT
          tyrosine_NN sulfated_JJ peptide_NN from_IN the_DT N-_NNP terminus_JJ of_IN the_DT
          coreceptor_NN CCR_NNP 5_CD [_NN 25_CD ]_NN ,_, shown_VBN to_TO inhibit_VB infection_NN by_IN
          CCR_NNP 5_CD -_: dependent_JJ ,_, but_CC not_RB CXCR_NNP 4_CD -_: dependent_JJ ,_, HIV-_NNP 1_CD isolates_VBZ ,_,
          was_VBD sufficient_JJ to_TO increase_VB the_DT expression_NN of_IN the_DT gp_NN 41_CD
          six-helix_JJ bundles_NNS in_IN HIV-_NNP 1_CD BaL_NNP virus_NN particles_NNS (_( Fig_NNP ._. 7_CD )_) ._.
          A_DT CCR_NNP 5_CD control_NN peptide_NN the_DT tyrosines_NNS of_IN which_WDT were_VBD not_RB
          sulfated_JJ did_VBD not_RB have_VB this_DT effect_NN ._. Analogous_NNP experiments_NNS
          with_IN HIV-_NNP 1_CD IIIB_NNP were_VBD not_RB performed_VBN since_IN there_EX are_VBP no_DT
          published_VBN data_NN concerning_VBG the_DT biological_JJ properties_NNS of_IN
          tyrosine_NN sulfated_JJ peptides_NNS from_IN the_DT N-_NNP terminus_JJ of_IN
          CXCR_NNP 4_CD ._.
          In_IN the_DT experiments_NNS described_VBD above_IN evidence_NN for_IN the_DT
          formation_NN of_IN gp_NN 41_CD six-helix_JJ bundles_NNS was_VBD obtained_VBN from_IN
          capture_NN of_IN CAP_NNP ,_, CD_NNP 4_CD and_CC CCR_NNP 5_CD S-_NNP peptide_NN treated_VBD virus_NN
          particles_NNS ,_, respectively_RB ,_, onto_IN wells_NNS coated_VBN with_IN mAb_NN NC-_NNP 1_CD ._.
          This_DT assay_NN is_VBZ equivalent_JJ to_TO an_DT immunoprecipitation_NN assay_NN
          with_IN solid_JJ phase_NN mAb_NN NC-_NNP 1_CD ._. In_IN order_NN to_TO provide_VB further_JJ
          evidence_NN for_IN the_DT induction_NN of_IN the_DT gp_NN 41_CD six-helix_JJ bundles_NNS
          by_IN the_DT distinct_JJ ligands_NNS binding_VBG to_TO the_DT HIV_NNP envelope_NN ,_, the_DT
          newly_RB formed_VBN structures_NNS in_IN virus_NN lysates_NNS were_VBD also_RB
          quantitated_JJ by_IN a_DT sandwich_NN ELISA_NNP [_NN 21_CD ]_NN ._. The_DT results_NNS not_RB
          only_RB unequivocally_RB confirmed_VBD the_DT induction_NN of_IN gp_NN 41_CD
          six-helix_JJ bundle_NN structures_NNS by_IN sCD_NN 4_CD ,_, CAP_NNP and_CC the_DT
          S-_NNP peptide_NN from_IN CCR_NNP 5_CD ,_, but_CC also_RB provided_VBN evidence_NN that_IN
          these_DT structures_NNS were_VBD undetectable_JJ in_IN untreated_JJ virus_NN
          particles_NNS (_( Fig_NNP ._. 8_CD )_) ._. CAP_NNP (_( 0_CD ._. 078_CD to_TO 10_CD mg_NN /_NN ml_NN )_) in_IN the_DT
          absence_NN of_IN virus_NN particles_NNS provided_VBD negative_JJ results_NNS in_IN
          this_DT assay_NN ._. The_DT CCR_NNP 5_CD peptide_NN lacking_VBG sulfated_JJ tyrosines_NNS
          did_VBD not_RB induce_VB the_DT six-helix_JJ bundles_NNS ._. Thus_RB ,_, it_PRP seems_VBZ
          likely_JJ that_IN the_DT detection_NN of_IN gp_NN 41_CD six-helix_JJ bundles_NNS in_IN
          untreated_JJ HIV-_NNP 1_CD using_VBG the_DT virion_NN capture_NN assay_NN was_VBD due_JJ to_TO
          their_PRP$ spontaneous_JJ formation_NN during_IN prolonged_JJ incubation_NN
          of_IN HIV-_NNP 1_CD in_IN these_DT tests_NNS ._. The_DT six-helix_JJ bundles_NNS were_VBD also_RB
          induced_VBN by_IN heating_VBG (_( 10_CD min_NN at_IN 60_CD °_NN C_NNP )_) HIV-_NNP 1_CD virus_NN particles_NNS
          (_( Fig_NNP ._. 8_CD )_) ._.
          In_IN summary_NN ,_, blocking_VBG by_IN CAP_NNP of_IN the_DT coreceptor_NN binding_JJ
          sites_NNS on_IN the_DT virus_NN envelope_NN glycoprotein_NN gp_NN 120_CD within_IN
          HIV-_NNP 1_CD virus_NN particles_NNS appears_VBZ to_TO induce_VB conformational_NN
          changes_NNS in_IN gp_NN 41_CD leading_VBG to_TO the_DT formation_NN of_IN six-helix_JJ
          bundle_NN structures_NNS ._.
        
        
          Shedding_NNP of_IN gp_NN 120_CD from_IN virus_NN particles_NNS
          It_PRP was_VBD reported_VBN that_DT treatment_NN of_IN HIV-_NNP 1_CD gp_NN 120_CD /_NN gp_NN 41_CD
          envelope_NN glycoprotein_NN oligomers_NNS with_IN sCD_NN 4_CD lead_VB to_TO
          shedding_NN of_IN gp_NN 120_CD -_: sCD_NN 4_CD complexes_NNS concomitant_NN with_IN
          increased_VBN exposure_NN of_IN some_DT cryptic_JJ epitopes_NNS on_IN gp_NN 41_CD [_NN 13_CD
          34_CD 35_CD ]_NN ._. Therefore_RB ,_, it_PRP was_VBD of_IN interest_NN to_TO determine_VB
          whether_IN or_CC not_RB shedding_NN of_IN gp_NN 120_CD from_IN virus_NN particles_NNS was_VBD
          required_VBN for_IN the_DT CAP_NNP induced_VBD exposure_NN of_IN binding_JJ sites_NNS
          for_IN mAb_NN NC-_NNP 1_CD on_IN gp_NN 41_CD ._. Treatment_NNP of_IN HIV-_NNP 1_CD IIIB_NNP and_CC BaL_NNP
          with_IN CAP_NNP did_VBD not_RB decrease_VB the_DT level_NN of_IN virus-associated_JJ
          gp_NN 120_CD in_IN comparison_NN with_IN control_NN virus_NN preparations_NNS
          (_( Table_NNP 3_LS )_) ._. The_DT results_NNS agree_VBP with_IN the_DT half_JJ life_NN of_IN 40_CD h_NN
          for_IN virus_NN associated_VBN gp_NN 120_CD in_IN the_DT course_NN of_IN spontaneous_JJ
          gp_NN 120_CD shedding_VBG from_IN HIV-_NNP 1_CD HXB_NNP 3_CD at_IN 37_CD °_NN C_NNP [_NN 36_CD ]_NN and_CC the_DT
          small_JJ sCD_NN 4_CD induced_VBN release_NN of_IN gp_NN 120_CD within_IN 5_CD min_NN at_IN 37_CD °_NN C_NNP
          [_NN 37_CD ]_NN ._. Thus_RB gp_NN 120_CD shedding_VBG was_VBD not_RB a_DT prerequisite_NN for_IN
          the_DT formation_NN of_IN gp_NN 41_CD six-helix_JJ bundles_NNS ._.
        
      
      
        Discussion_NNP
        Earlier_JJR studies_NNS [_NN 8_CD ]_NN indicated_VBD that_IN CAP_NNP treated_VBD HIV-_NNP 1_CD
        particles_NNS have_VBP their_PRP$ coreceptor_NN ,_, i_NNP ._. e_SYM ._. CXCR_NNP 4_CD and_CC CCR_NNP 5_CD ,_,
        binding_JJ sites_NNS obstructed_VBN ,_, while_IN sites_NNS involved_VBN in_IN
        association_NN with_IN CD_NNP 4_CD appeared_VBD unaffected_JJ ._. This_DT suggested_VBD
        that_IN HIV-_NNP 1_CD could_MD bind_NN CD_NNP 4_CD and_CC CAP_NNP at_IN the_DT same_JJ time_NN ,_,
        independently_RB ._. Since_IN association_NN with_IN CD_NNP 4_CD induces_VBZ
        conformational_NN changes_NNS in_IN the_DT HIV-_NNP 1_CD envelope_NN glycoprotein_NN
        gp_NN 120_CD [_NN 14_CD 16_CD 17_CD ]_NN ,_, it_PRP was_VBD of_IN interest_NN to_TO determine_VB :_: (_( a_DT )_)
        whether_IN CD_NNP 4_CD binding_JJ to_TO HIV-_NNP 1_CD would_MD affect_VB subsequent_JJ
        association_NN of_IN the_DT virus_NN with_IN CAP_NNP and_CC (_( b_SYM )_) the_DT consequences_NNS
        of_IN both_DT CD_NNP 4_CD and_CC CAP_NNP binding_JJ to_TO virus_NN particles_NNS ._. First_LS ,_, it_PRP
        was_VBD found_VBN that_DT pretreatment_NN of_IN gp_NN 120_CD with_IN sCD_NN 4_CD enhanced_VBN
        subsequent_JJ binding_JJ with_IN CAP_NNP (_( Fig_NNP ._. 1_LS )_) ._. This_DT could_MD be_VB
        ascribed_VBN to_TO conformational_NN changes_NNS in_IN gp_NN 120_CD ,_, to_TO the_DT
        concealment_NN of_IN surface_NN areas_NNS with_IN the_DT greatest_JJS negative_JJ
        charge_NN on_IN gp_NN 120_CD by_IN CD_NNP 4_CD [_NN 16_CD ]_NN ,_, (_( Fig_NNP ._. 9_CD )_) ,_, which_WDT could_MD
        diminish_VB the_DT electrostatic_JJ attraction_NN between_IN gp_NN 120_CD and_CC
        negatively_RB charged_VBN CAP_NNP ,_, or_CC to_TO additional_JJ CAP_NNP binding_JJ sites_NNS
        on_IN the_DT CD_NNP 4_CD portion_NN of_IN gp_NN 120_CD -_: sCD_NN 4_CD complexes_NNS ._. The_DT binding_JJ of_IN
        HIV-_NNP 1_CD with_IN CAP_NNP was_VBD similarly_RB enhanced_VBN by_IN pretreatment_NN with_IN
        sCD_NN 4_CD (_( Fig_NNP ._. 2_LS )_) ,_, the_DT effect_NN being_VBG much_RB more_RBR pronounced_JJ with_IN
        the_DT R_NN 5_CD virus_NN ,_, HIV-_NNP 1_CD BaL_NNP ,_, in_IN comparison_NN with_IN the_DT X_NNP 4_CD virus_NN ,_,
        HIV-_NNP 1_CD IIIB_NNP ._. These_DT observations_NNS may_MD be_VB related_VBN to_TO the_DT
        recognized_VBN role_NN of_IN CD_NNP 4_CD in_IN inducing_VBG conformational_NN changes_NNS
        in_IN gp_NN 120_CD that_WDT contribute_VBP to_TO the_DT exposure_NN of_IN binding_JJ sites_NNS
        for_IN CXCR_NNP 4_CD and_CC CCR_NNP 5_CD [_NN 16_CD 17_CD 38_CD ]_NN ._.
        Furthermore_RB ,_, it_PRP seemed_VBD important_JJ to_TO determine_VB whether_IN
        simultaneous_JJ CD_NNP 4_CD and_CC enhanced_VBN CAP_NNP binding_JJ to_TO HIV-_NNP 1_CD would_MD
        result_VB in_IN synergistic_JJ effects_NNS for_IN inhibition_NN of_IN HIV-_NNP 1_CD
        infection_NN ._. Evidence_NN for_IN such_JJ synergism_NN was_VBD indeed_RB
        established_VBN (_( Table_NNP 1_CD and_CC 2_CD ,_, Fig_NNP ._. 3_LS )_) ._.
        Earlier_JJR studies_NNS [_NN 8_CD ]_NN ,_, in_IN which_WDT the_DT binding_JJ of_IN CAP_NNP
        treated_VBD and_CC untreated_JJ virus_NN to_TO antibodies_NNS specific_JJ for_IN
        distinct_JJ regions_NNS on_IN the_DT envelope_NN glycoproteins_NNS gp_NN 120_CD and_CC
        gp_NN 41_CD was_VBD studied_VBN ,_, indicated_VBD that_IN CAP_NNP caused_VBD decreased_VBD
        binding_JJ with_IN antibodies_NNS against_IN several_JJ peptides_NNS from_IN gp_NN 120_CD
        but_CC only_RB with_IN a_DT single_JJ antibody_NN against_IN peptide_NN 557_CD -_: 586_CD
        from_IN gp_NN 41_CD (_( for_IN numbering_VBG of_IN amino_JJ acid_NN residues_NNS see_VBP our_PRP$
        earlier_JJR publication_NN [_NN 39_CD ]_NN )_) ._. Thus_RB ,_, there_EX are_VBP fewer_RBR binding_JJ
        sites_NNS for_IN CAP_NNP on_IN gp_NN 41_CD than_IN on_IN gp_NN 120_CD ._. Interestingly_RB ,_,
        molecular_JJ docking_VBG studies_NNS revealed_VBD that_IN phthalic_JJ and_CC acetic_JJ
        acid_NN anhydride_NN modified_VBN cellotetratose_NN ,_, a_DT subunit_NN of_IN CAP_NNP ,_,
        docked_JJ to_TO a_DT single_JJ site_NN on_IN the_DT gp_NN 41_CD core_NN structure_NN
        overlapping_VBG the_DT peptide_NN 557_CD -_: 586_CD (_( Fig_NNP ._. 10_CD )_) ._. This_DT region_NN is_VBZ
        in_IN the_DT vicinity_NN of_IN the_DT most_RBS prominent_JJ positively_RB charged_VBN
        areas_NNS on_IN the_DT surface_NN of_IN the_DT gp_NN 41_CD core_NN which_WDT has_VBZ an_DT overall_JJ
        negative_JJ charge_NN ._. Since_IN CAP_NNP blocks_NNS coreceptor_NN binding_JJ sites_NNS
        on_IN gp_NN 120_CD [_NN 8_CD ]_NN it_PRP was_VBD of_IN interest_NN to_TO determine_VB whether_IN this_DT
        blockade_NN would_MD lead_VB to_TO conformational_NN changes_NNS in_IN HIV-_NNP 1_CD
        gp_NN 41_CD ,_, similar_JJ to_TO those_DT elicited_JJ by_IN CD_NNP 4_CD or_CC coreceptor_NN
        binding_JJ to_TO gp_NN 120_CD ._.
        The_DT occupancy_NN of_IN CD_NNP 4_CD and_CC coreceptor_NN binding_JJ sites_NNS by_IN
        their_PRP$ respective_JJ ligands_NNS elicits_NNS downstream_JJ conformational_NN
        changes_NNS in_IN the_DT envelope_NN glycoprotein_NN gp_NN 41_CD ,_, rendering_VBG it_PRP
        competent_JJ for_IN fusion_NN between_IN virus_NN and_CC target_NN cell_NN
        membranes_NNS [_NN 18_CD 19_CD 40_CD 41_CD 42_CD 43_CD ]_NN ._. Shedding_NNP of_IN gp_NN 120_CD from_IN
        virus_NN particles_NNS is_VBZ not_RB required_VBN for_IN subsequent_JJ membrane_NN
        fusion_NN events_NNS [_NN 44_CD ]_NN ._. The_DT induction_NN of_IN gp_NN 41_CD six-helix_JJ
        bundles_NNS ,_, detectable_JJ by_IN mAb_NN NC-_NNP 1_CD ,_, by_IN CAP_NNP in_IN the_DT absence_NN of_IN
        gp_NN 120_CD shedding_VBG is_VBZ consistent_JJ with_IN this_DT conclusion_NN ._. The_DT
        conformational_NN changes_NNS lead_VBP to_TO the_DT formation_NN of_IN a_DT
        coiled-coil_JJ in_IN gp_NN 41_CD ,_, consisting_VBG of_IN three_CD NH_NNP 
        2_CD -_: terminal_NN leucine_NN /_NN isoleucine_NN zipper_NN
        regions_NNS ,_, each_DT contributed_VBN by_IN one_CD of_IN the_DT three_CD subunits_NNS of_IN
        the_DT envelope_NN glycoprotein_NN trimer_NN ._. In_IN the_DT presence_NN of_IN target_NN
        cell_NN membranes_NNS ,_, the_DT NH_NNP 
        2_CD -_: terminal_NN fusion_NN peptide_NN is_VBZ displaced_VBN
        in_IN the_DT direction_NN of_IN the_DT target_NN cell_NN membrane_NN ,_, into_IN which_WDT it_PRP
        inserts_NNS ._. Thus_RB ,_, the_DT HIV-_NNP 1_CD envelope_NN glycoprotein_NN gp_NN 41_CD becomes_VBZ
        an_DT integral_JJ component_NN of_IN two_CD membranes_NNS ,_, the_DT viral_JJ membrane_NN
        and_CC the_DT cellular_JJ membrane_NN ._. The_DT outer_JJ surface_NN of_IN the_DT
        coiled-coil_JJ contains_VBZ grooves_NNS into_IN which_WDT three_CD heptad_NN repeat_NN
        regions_NNS from_IN the_DT C-_NNP terminal_NN part_NN of_IN the_DT gp_NN 41_CD ectodomain_NN
        pack_NN ,_, resulting_VBG in_IN a_DT stable_JJ six-helix_JJ bundle_NN [_NN 42_CD 45_CD 46_CD 47_CD
        48_CD 49_CD 50_CD 51_CD 52_CD 53_CD 54_CD ]_NN ._. The_DT six-helix_JJ bundle_NN structure_NN can_MD
        be_VB detected_VBN by_IN specific_JJ antibodies_NNS [_NN 14_CD 20_CD 43_CD 55_CD ]_NN ._.
        Results_NNS presented_VBN here_RB indicate_VBP that_IN purified_JJ HIV-_NNP 1_CD
        particles_NNS do_VBP not_RB contain_VB detectable_JJ six-helix_JJ bundle_NN
        structures_NNS ._. Their_PRP$ expression_NN is_VBZ induced_VBN by_IN CAP_NNP treatment_NN of_IN
        the_DT virus_NN (_( Fig_NNP ._. 5_LS and_CC 8_CD )_) ._. Prior_RB engagement_NN of_IN CD_NNP 4_CD binding_JJ
        sites_NNS is_VBZ not_RB required_VBN for_IN the_DT induction_NN of_IN the_DT six-helix_JJ
        bundles_NNS by_IN CAP_NNP ,_, but_CC increases_VBZ their_PRP$ expression_NN (_( Fig_NNP ._. 5_LS and_CC
        8_CD )_) ._. The_DT apparent_JJ cooperativity_NN between_IN CAP_NNP and_CC sCD_NN 4_CD in_IN
        induction_NN of_IN the_DT gp_NN 41_CD six-helix_JJ bundle_NN structures_NNS may_MD
        possibly_RB be_VB related_VBN to_TO the_DT observed_VBN synergism_NN between_IN these_DT
        two_CD ligands_NNS for_IN inhibition_NN of_IN HIV-_NNP 1_CD infection_NN (_( Table_NNP 1_CD and_CC
        2_CD ,_, Fig_NNP ._. 3_LS )_) ._. The_DT hypothesis_NNS that_WDT engagement_NN of_IN coreceptor_NN
        binding_JJ sites_NNS on_IN gp_NN 120_CD by_IN CAP_NNP leads_VBZ to_TO the_DT expression_NN of_IN
        gp_NN 41_CD six-helix_JJ bundle_NN structures_NNS is_VBZ supported_VBN by_IN the_DT
        finding_VBG that_IN a_DT tyrosine_NN sulfated_JJ S-_NNP peptide_NN ,_, but_CC not_RB the_DT
        non-sulfated_JJ peptide_NN ,_, from_IN the_DT N-_NNP terminus_JJ of_IN CCR_NNP 5_CD [_NN 25_CD 56_CD
        57_CD ]_NN has_VBZ an_DT effect_NN similar_JJ to_TO that_DT of_IN CAP_NNP (_( Fig_NNP ._. 7_CD )_) ._. The_DT
        helix-bundles_JJ were_VBD also_RB induced_VBN by_IN heating_VBG HIV-_NNP 1_CD virus_NN
        particles_NNS at_IN 60_CD °_NN C_NNP ,_, in_IN agreement_NN with_IN the_DT irreversible_JJ
        induction_NN of_IN the_DT fusogenic_JJ conformation_NN in_IN influenza_NN virus_NN
        hemagglutinin_NN by_IN heat_NN [_NN 58_CD 59_CD ]_NN
        In_IN summary_NN ,_, the_DT results_NNS presented_VBN here_RB suggest_VBP that_DT
        treatment_NN of_IN HIV-_NNP 1_CD with_IN CAP_NNP leads_VBZ to_TO conformational_NN changes_NNS
        in_IN the_DT envelope_NN glycoproteins_NNS ,_, ultimately_RB resulting_VBG ,_, in_IN the_DT
        absence_NN of_IN target_NN cell_NN membranes_NNS ,_, in_IN the_DT formation_NN of_IN gp_NN 41_CD
        six-helix_JJ bundles_NNS ._. These_DT structures_NNS are_VBP extremely_RB stable_JJ
        and_CC represent_VB a_DT terminal_NN ,_, functionally_RB inactive_JJ viral_JJ
        constituent_NN [_NN 54_CD 60_CD ]_NN ;_: (_( Fig_NNP ._. 11_CD )_) ,_, analogous_JJ to_TO that_DT of_IN
        inactivated_JJ influenza_NN virus_NN hemagglutinin_NN HA_NNP 2_CD exposed_VBN to_TO
        low_JJ pH_NN in_IN the_DT absence_NN of_IN cell_NN membranes_NNS [_NN 59_CD 61_CD 62_CD 63_CD 64_CD ]_NN
        ._.
      
      
        Conclusions_NNP
        Earlier_JJR studies_NNS describing_VBG the_DT underlying_VBG molecular_JJ
        mechanisms_NNS involved_VBN in_IN the_DT HIV-_NNP 1_CD inhibitory_NN effect_NN of_IN the_DT
        candidate_NN microbicide_NN CAP_NNP indicated_VBD that_IN this_DT compound_NN
        remains_VBZ bound_VBN to_TO HIV-_NNP 1_CD ,_, impairing_VBG virus_NN infectivity_NN by_IN
        blockade_NN of_IN binding_JJ sites_NNS for_IN cellular_JJ coreceptors_NNS CXCR_NNP 4_CD
        and_CC CCR_NNP 5_CD [_NN 8_CD ]_NN ._. Results_NNS reported_VBD here_RB further_JJ extend_VB these_DT
        findings_NNS and_CC show_NN that_IN :_: 1_LS )_) there_EX is_VBZ synergism_NN between_IN sCD_NN 4_CD
        and_CC CAP_NNP for_IN inhibition_NN of_IN virus_NN infectivity_NN ;_: 2_LS )_) CAP_NNP binding_JJ
        to_TO HIV-_NNP 1_CD leads_VBZ to_TO conformational_NN changes_NNS in_IN viral_JJ envelope_NN
        glycoproteins_NNS resulting_VBG in_IN the_DT expression_NN of_IN functionally_RB
        inert_NN six-helix_JJ bundle_NN structures_NNS ._.
        To_TO the_DT best_JJS of_IN our_PRP$ knowledge_NN ,_, results_NNS reported_VBD here_RB and_CC
        earlier_JJR [_NN 8_CD ]_NN represent_VBP the_DT most_RBS detailed_JJ study_NN on_IN the_DT
        mechanism_NN of_IN action_NN of_IN a_DT polymeric_JJ anti-_NN HIV-_NNP 1_CD compound_NN and_CC
        offer_VB new_JJ opportunities_NNS for_IN microbicide_NN research_NN ,_, including_VBG
        the_DT design_NN of_IN combined_VBN microbicides_NNS with_IN distinct_JJ target_NN
        sites_NNS on_IN HIV-_NNP 1_CD and_CC acting_VBG synergistically_RB ._.
      
      
        List_NN of_IN abbreviations_NNS
        CAP_NNP ,_, cellulose_NN acetate_NN phthalate_NN ;_: STD_NNP ,_, sexually_RB
        transmitted_VBD disease_NN ;_: ELISA_NNP ,_, enzyme-linked_JJ immunosorbent_NN
        assay_NN ;_: mAbs_NNS ,_, monoclonal_NN antibodies_NNS ;_: FBS_NNP ,_, fetal_JJ bovine_JJ
        serum_NN ;_: PEG_NNP 6000_CD ,_, polyethylene_NN glycol_NN 6000_CD ;_: HIV-_NNP 1_CD ,_, human_JJ
        immunodeficiency_NN virus_NN type_NN 1_CD ;_: BSA_NNP ,_, bovine_JJ serum_NN albumin_NN ;_:
        PBS_NNP ,_, phosphate_NN buffered_JJ saline_NN ;_: Ch-_NNP PBS_NNP ,_, chicken_NN serum_NN (_( 10_CD %_NN )_)
        in_IN PBS_NNP ;_: PBS-BG_NNP ,_, 1_CD %_NN BSA_NNP /_NN 1_CD %_NN gelatin_NN in_IN PBS_NNP ;_: HRP_NNP ,_, horseradish_NN
        peroxidase_NN ;_: sCD_NN 4_CD ,_, soluble_JJ CD_NNP 4_CD ;_: TS_NNP ,_, 0_CD ._. 14_CD M_NNP NaCl_NNP ,_, 0_CD ._. 01_CD M_NNP
        Tris_NNP ,_, pH_NN 7_CD ._. 0_CD ;_: CTAP_NNP ,_, cellotetraose_NN acetate_NN phthalate_NN ;_: pdb_NN ,_,
        Protein_NNP Data_NNP Bank_NNP ;_: ED_NNP 
        50_CD ,_, effective_JJ dose_NN for_IN 50_CD %_NN
        inhibition_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD
      
      
        Authors_NNP '_'' contributions_NNS
        Author_NN 1_CD ARN_NNP developed_VBD the_DT concepts_NNS representing_VBG the_DT
        basis_NN of_IN the_DT manuscript_NN and_CC designed_VBN most_JJS experiments_NNS ._.
        Author_NN 2_CD NS_NNP carried_VBD out_IN most_JJS experiments_NNS and_CC contributed_VBD to_TO
        the_DT development_NN of_IN experimental_JJ techniques_NNS ._. Author_NN 3_CD SJ_NNP
        developed_VBD monoclonal_NN antibody_NN NC-_NNP 1_CD and_CC was_VBD involved_VBN in_IN
        studies_NNS on_IN the_DT gp_NN 41_CD six_CD helix_NN bundles_NNS and_CC on_IN synergism_NN
        between_IN CAP_NNP and_CC sCD_NN 4_CD for_IN inhibition_NN of_IN HIV-_NNP 1_CD infectivity_NN ._.
        Author_NN 4_CD YYL_NNP did_VBD most_JJS tissue_NN culture_NN work_NN and_CC infectivity_NN
        assays_NNS ._. Author_NN 5_CD AKD_NNP did_VBD all_PDT the_DT molecular_JJ modeling_NN
        studies_NNS ._.
      
    
  
